LIVE POLIO IRUS VACCINES

364
Efficacy-Laboratory Evidence
TABLE 8.
VIREMIA IN RELATION TO PREVACCINE ANTIBODY STATUS
ANTIBODY TITER
TYPE I
LEss THAN 4, NUMBER VIRUS RATIO
BY TYPES OF PERSONS ISOLATED
ANTIBODY TITER
TYPE III
LEss THAN 4, NUMlBER VIRUS RATIO
BY TYPEs OF PERSONS ISOLATED
I, II, and III 5 4 1:1.25
I and II 9 2 1:4.5
I and III
I 10 1 1:10
TOTAL 24 7 1: 3.4
I, II, and III 5 0 0
I and III 11 0 0
II and III
III 28 1 1: 28
TOTAL 44 1 1:44
or perhaps whole laked blood could be used as
inocula, a larger number of virus isolations would
have been accomplished. No clinical evidence of
illness was present at the time of viremia in the
eight people from whose blood serum virus was
isolated. It is of interest that Type 1 poliovirus
was isolated from seven persons and Type 3 virus
was isolated only once. In no instance was Type
2 poliovirus isolated from the blood. Whether
this represents a strain difference or a type difference
remains to be studied. Approximately
one and three quarter million people have ingested
the oral poliomyelitis vaccine virus strains
reported in this study. On the basis of the data
presented, it is reasonable to suppose that thousands
of persons who have ingested the vaccine
have had a viremia with one or perhaps more of
the vaccine virus types, yet illnesses among these
vaccinees which can be causally associated with
the vaccine, if any, have not been proven.
REFERENCE
1. Barr, Robert N., Bauer, Henry, Kleinman,
Herman, Johnson, Eugene A., Martins da
Silva, Mauricio, Kimball, Anne C., and
Cooney, Marion K.: Use of orally administered
live attenuated polioviruses as a vaccine in a
community setting: A controlled study. J. Am.
M. Assn. 170: 893-905 (June 20) 1959.